4-(4-Chloro-phenylsulfanylmethyl)-piperidine hydrochloride, 95.0%, 250mg

(S,S)-(-)-1,2-Diaminocyclohexane-D-Tartrate, 95.0%, 25g

EDTA-Manganese disodium salt x 2H2O, min. 93%, for synthesis, 500 g, plastic packaging.

Methyl 2-formyl-4-methyl-4H-furo[3,2-b]pyrrole-5-carboxylate, 1g

Ethyl 2-bromo-3-fluorobenzoate, 5g

z-d-glu(obzl)-oh, 95.0%, 1g

3-(benzyloxy)-2,2-dimethylcyclobutan-1-one, 5g

enoximone, 98%, 5mg

7-Bromo-2-chloro-quinoline, 96.0%, 5g

N,N-dibutyl-4-(7-ethyl-3-(2-fluorophenyl)-3,7-dihydropyrano[2,3-c]carbazol-3-yl)aniline, 95+%, 250mg

4-chloro-6-methyl-5-(4-methylphenyl)thieno[2,3-d]pyrimidine, 95.0%, 250mg

5-Fluoro-2-(piperidin-3-yloxy)pyrimidinehydrochloride, 1g

5-Bromo-4-methylisoquinoline, 95.0%, 10g